Sevelamer

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Sevelamer
   1. Pharmacist Assessment Report
   2. Sevelamer: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Sevelamer: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Sevelamer, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	2
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
hyperphosphatemia	licence in another country
renal dialysis	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
11838C	Sevelamer Lupin	Tablet containing sevelamer carbonate 80	Valid

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety warnings and contraindications.

• Knowledge-graph contraindication signals (from drug-disease relationships in a knowledge graph, not from label text): vitamin D deficiency, osteomalacia, rickets, hypophosphataemia and gastroparesis. These should be verified against the PI.
• Drug Interactions (DDInter, 100 interactions recorded). The moderate-level interactions include:
  • Cholecalciferol
  • Calcifediol
  • Calcitriol
  • Dihydrotachysterol
  • Ergocalciferol
  • Levofloxacin
  • Vitamin A

  Other recorded interactions have an unclassified severity, including pantoprazole, omeprazole, lansoprazole, cimetidine, vancomycin, morphine, prednisone and acarbose. Co-administration timing with other oral medicines should be checked against the PI.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---